SOShinya Okumura

Shinya Okumura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shinya Okumura has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pancreas–Intestine Composite Transplantation for Simultaneous Loss of Pancreatic and Intestinal Function (With Video)

    by Kei Yamane, Takashi Ito, Takayuki Anazawa, Junji Fujikura, Makoto Okabe, Satoshi Ishida, Koki Kurahashi, Masaaki Hirata, Hiroshi Kawamoto, Hiroto Nishino, et al.

    Pancreas–intestine composite transplantation (PITx) is a therapeutic option for patients with irreversible loss of both pancreatic and intestinal function. We report a case of PITx in a 16‐year‐old male who developed fulminant Type 1 diabetes mellitus complicated by non‐occlusive mesenteric ischemia, resulting in extensive intestinal necrosis. Despite intensive surgical and critical care management, the patient ultimately required total small intestinal resection and total pancreatectomy. After recovery from sepsis and multiorgan dysfunction, the patient's general condition stabilized, and PITx was considered an appropriate therapeutic option. The composite graft consisted of the pancreas, duodenum, small intestine, and right colon. Arterial inflow was reconstructed using a single Carrel patch incorporating the celiac axis and superior mesenteric artery, and venous outflow was established by portal vein anastomosis. Postoperatively, pancreatic endocrine function was restored, allowing stable glycemic control without exogenous insulin, and intestinal graft function enabled the gradual advancement of enteral and oral nutrition. This report highlights the key technical considerations and anatomical principles of PITx and demonstrates that tailored composite graft transplantation can restore both pancreatic and intestinal function while preserving unaffected abdominal organs in highly selected patients with combined pancreatic and intestinal failure.

  • Open Access

    Notation System for Liver Transplant Recipients: Key Information in Transplant Procedure

    by Hidenobu Kojima, Takashi Ito, Kei Yamane, Tomoaki Yoh, Shinya Okumura, Katsunori Sakamoto, Shoichi Kageyama, Satoshi Ogiso, Takayuki Anazawa, Yoichiro Uchida, et al.

    Liver transplantation (LT) is a standard therapy for patients with end‐stage liver disease and certain hepatic malignancies. The LT procedure has diversified due to donor shortages and advances in immunosuppressive treatments and surgical techniques. Donor organ shortages have promoted the use of living donor liver transplantation and “marginal” livers, including donation after circulatory death. ABO‐incompatible liver transplants now show outcomes comparable with ABO‐compatible transplants when a desensitization protocol is used. Hepaticojejunostomy, rather than duct‐to‐duct anastomosis, is performed in select cases with an unsuitable common bile duct or in patients with primary sclerosing cholangitis. These procedural differences affect follow‐up management in LT recipients. Given the increasing diversity of transplant surgeries and the long‐term prognosis after LT, it is essential for healthcare professionals and transplant societies to be informed about the specific procedures performed in LT recipients. We aimed to propose a notation system for LT recipients that documents key procedural information, including the number of transplantations, donor type with donor/recipient blood types in ABO‐incompatible transplantation, graft type, the number of reconstructed vessels, and the number and type of biliary reconstruction. The use of a common notation system for transplant procedures can facilitate patient management, communication, and accurate understanding of transplant procedures.

  • Long‐Term Outcomes of Living Donor Liver Transplantation in Children With Alagille Syndrome: Results From Vanguard Multicenter Study of International Living Donor Liver Transplantation Group

    by Yusuke Yanagi, Sinya Okumura, Taiichi Wakiya, Yuta Hirata, Jiyoung Kim, Masaki Honda, Kazuya Hirukawa, Tonguc Utku Yilmaz, Takanobu Hara, Toru Ikegami, et al.

    Background: The morbidity and mortality after living donor liver transplantation (LDLT) in children with Alagille syndrome (AGS) are complex because of the multisystem involvement of the disease. Evidence on long‐term outcomes and donor selection remains limited. Methods: This multicenter retrospective study included 49 pediatric patients with AGS who underwent LDLT between 2001 and 2020 at eight institutions in Japan, Korea, and Turkey. Clinical characteristics, transplant indications, donor selection, posttransplant growth, renal function, and complications were analyzed. Results: The median age at LDLT was 1.1 years. Major indications for transplantation were severe growth failure (91.8%) and advanced liver disease with hepatic dysfunction. Based on donor evaluations, 11% of candidates were excluded due to genetic or anatomical concerns. The 5‐year patient and graft survival rates were 93.7% and 91.5%, respectively. LDLT before 2 years of age was associated with significantly greater catch‐up in height and weight. Long‐term renal deterioration was observed, particularly beyond 15 years after transplantation, and older age at LDLT was an independent predictor of lower long‐term estimated glomerular filtration rate. Cardiac anomalies were manageable with appropriate preoperative evaluation, whereas vasculopathies were observed after adolescence. A history of Kasai portoenterostomy did not significantly affect posttransplant outcomes. Conclusions: LDLT provides excellent short‐ and long‐term outcomes in pediatric AGS. Timely LT may improve growth and preserve renal function before progressive multisystem complications become established. Long‐term surveillance and comprehensive donor evaluation remain essential.

  • Treatment Interval as a Prognostic Marker in Patients Undergoing Repeated Curative‐Intent Local Treatment for Recurrent Hepatocellular Carcinoma

    by Katsunori Sakamoto, Tomoaki Yoh, Satoshi Nomura, Kentaro Kadono, Hidenobu Kojima, Asahi Sato, Shoichi Kageyama, Hirofumi Hirao, Takahiro Nishio, Shinya Okumura, et al.

    Purpose: This study aimed to investigate the prognostic impact of the interval between curative‐intent local treatments in patients undergoing repeated therapies for recurrent hepatocellular carcinoma after hepatectomy. Methods: The present retrospective cohort study included 890 patients who underwent hepatectomy for HCC at our hospital between 2001 and 2020. Overall survival (OS) was evaluated from the time of each curative‐intent local treatment, according to the number of treatments received and the intervals between consecutive curative‐intent treatments for intrahepatic recurrence, up to the fourth session. Results: During follow‐up, 625 patients (65.9%) developed intrahepatic recurrence. The median intervals gradually shortened to 24.9, 14.5, 12.4, and 12.8 months from hepatectomy to the first curative treatment, from the first to the second, from the second to the third, and from the third to the fourth treatments, respectively. For the first and second curative treatments, the pretreatment interval was not an independent predictor of OS. At the third curative treatment, an interval < 18.6 months between the second and third curative treatments independently predicted poorer OS (hazard ratio [HR] 2.280 and 95% confidence interval [CI] 1.046–4.967). For the fourth curative treatment, an interval < 14.1 months between the third and fourth treatments was an independent adverse prognostic factor (HR 4.961, 95% CI 1.607–15.319). The prognostic impact of treatment interval was more pronounced in patients who underwent ≥ 3 treatments, with a significant interaction compared with < 3 treatments. Conclusions: Among patients who remained eligible for repeated curative‐intent local treatment, a shortened interval between treatments in late‐phase recurrence was an independent predictor of poor prognosis.

  • Outcomes After Unsuccessful Revascularization Following Hepatic Artery Occlusion in Living Donor Liver Transplantation: Results From an International Multicenter Study

    by Takanobu Hara, Ryugen Takahashi, Robert C. Minnee, Takeo Toshima, Tonguc Utku Yilmaz, Daniel Reis Waisberg, Shinya Okumura, Keita Shimata, Sathish Kumar Krishnan, Daniel Zamora-Valdés, et al.

    Hepatic arterial occlusion after living donor liver transplantation (LDLT) can be catastrophic, yet outcomes when revascularization fails are incompletely defined. We conducted a retrospective multicenter cohort study across 10 International Living Donor Liver Transplantation Group institutions (2008–2022), including LDLT recipients in whom durable hepatic arterial inflow could not be achieved—either intraoperatively or after postoperative occlusion despite surgical or endovascular attempts. Twenty‐five patients met criteria. Median time to occlusion was 8 days (IQR 2–46). Etiologies were hepatic artery thrombosis (72%), occlusion after transarterial embolization (12%), intimal dissection (12%), and severe anastomotic stricture (4%). Diagnosis was imaging‐based in 84%. Revascularization was attempted in 16 patients, restoring temporary flow in 6. Portal vein arterialization was used in 3 intraoperative failures. Biliary complications occurred in 56%, and infectious complications in 76%. Collateral‐driven restoration of arterial flow occurred in 3 patients, and all three remain alive without graft failure. Using the date of failed revascularization as time zero, graft survival at 1/3/5 years was 48%/31%/23% (median 306 days, IQR 21‐604), and overall survival 60%/50%/50% (median 574 days, IQR 65‐1926); seven patients underwent retransplantation (median 430 days). Failure to revascularize within 30 days was associated with worse overall survival, while graft survival was similar. Unsuccessful revascularization after LDLT predicts poor graft outcomes with substantial biliary and infectious morbidity; collateral reperfusion, though uncommon, may enable long‐term graft survival.

  • Open Access

    Traumatic Ruptured Hepatic Cyst Managed by Laparoscopic Fenestration Assisted With Indocyanine Green (ICG) Fluorescence: A Case Report

    by Rikuto Uryu, Hirofumi Hirao, Kazuyuki Nagai, Satoshi Ogiso, Shinya Okumura, Tomoaki Yoh, Kei Yamane, Etsuro Hatano

    Nonparasitic hepatic cysts are common and generally asymptomatic. However, complications such as infection, hemorrhage, or rupture of the cyst necessitate therapeutic intervention. We report a rare case of traumatic rupture of a large hepatic cyst managed laparoscopically with the assistance of indocyanine green (ICG) fluorescence. A 57‐year‐old woman had been followed for 2 years for a large cystic lesion in segments 4 (S4) and 8 (S8) of the liver, suspected to be a mucinous cystic neoplasm (MCN). As the S4 cyst grew to 15 cm, surgical resection was planned. However, she presented to our emergency department after blunt abdominal trauma sustained from a fall at home. Computed tomography (CT) revealed rupture of the S4 cyst with massive ascites. Although initially managed conservatively with little abdominal symptoms, she developed worsening abdominal pain and progressive anemia 2 days postadmission, raising concern for cyst‐related hemorrhage and possible bile leakage. Emergent laparoscopic surgery revealed hemoperitoneum and bleeding from the ruptured cyst wall. ICG was administered intravenously immediately after anesthesia induction to visualize the communication between the cyst and the biliary tract by fluorescence imaging. Then, laparoscopic fenestration was performed under ICG guidance. The patient was discharged on postoperative day (POD) 6 without any complications. We successfully treated a rare case of traumatic hepatic cyst rupture by laparoscopic fenestration with ICG imaging. ICG fluorescence was a helpful adjunct for intraoperative assessment of the potential bile duct in the cyst, ensuring the safety of the operative procedure.

  • Open Access

    Pancreatic Neuroendocrine Tumor with Acinar Pattern Mimicking Pancreatic Ductal Adenocarcinoma: A Case Report

    by Yasunori Shirakawa, Kei Yamane, Kazuyuki Nagai, Shinya Otsuki, Masakazu Fujimoto, Kentaro Tsuji, Tomoaki Yoh, Shinya Okumura, Hirofumi Hirao, Satoshi Ogiso, et al.

    INTRODUCTION: Pancreatic neuroendocrine tumors (PanNETs) are rare, but their incidence has been increasing. PanNETs are usually diagnosed based on typical radiological and pathological findings. However, some exhibit unusual findings; therefore, we need to consider these and make a diagnosis through multidisciplinary evaluation. In this report, we present a case of PanNET that was challenging to diagnose preoperatively.CASE PRESENTATION: A man in his 70s with a prior diagnosis of intrahepatic cholangiocarcinoma (iCCA) was referred to our hospital (Kyoto University Hospital) for suspected recurrence of multiple intrahepatic metastases. MRI showed space-occupying lesions in the liver and a 2.7-cm hyperintense mass in the uncinate process of the pancreas. Adenocarcinoma was diagnosed by endoscopic US-guided tissue acquisition (EUS-TA) of the pancreatic lesion. Accordingly, the patient underwent neoadjuvant chemotherapy followed by pancreatoduodenectomy. However, postoperative histological and immunohistochemical evaluations of the surgically resected specimen revealed G2 PanNET with an unusual acinar structure that was not considered preoperatively.CONCLUSIONS: This case highlights the diagnostic challenge of unusual PanNETs that presented radiologically and pathologically with unusual features. A multidisciplinary evaluation and awareness of PanNETs with unusual features are essential for accurate diagnosis.

  • Robotic Hepatectomy Using the Hugo RAS System: Initial Experience and Technical Considerations

    by Katsunori Sakamoto, Hiroto Nishino, Tomoaki Yoh, Hidenobu Kojima, Asahi Sato, Hirofumi Hirao, Takahiro Nishio, Shinya Okumura, Daisuke Ueda, Kei Yamane, et al.

    Robotic hepatectomy using the Hugo robotic‐assisted surgery (RAS) system has recently been introduced; however, clinical experience remains limited. We report our initial experience in five patients, focusing on surgical techniques and short‐term outcomes. All procedures were completed robotically without conversion to open or laparoscopic surgery. The median operative time was 175 min (range, 162–209), and the median console time was 100 min (range, 79–139). The median inflow occlusion time was 31 min (range, 14–62). Intraoperative blood loss was minimal, with a median of 0 mL (range, 0–10). No intraoperative or postoperative complications were observed. The median postoperative hospital stay was 7 days (range, 4–11). The series included lesions in both left‐ and right‐sided liver segments, including technically demanding areas such as segment 7. These findings suggest that Hugo RAS minor hepatectomy appears feasible and safe in selected cases, with favorable short‐term outcomes.